---
# Documentation: https://wowchemy.com/docs/managing-content/

title: Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid
  Cells, and Plasmablasts as Hallmarks of Severe COVID-19
subtitle: ''
summary: ''
authors:
- Joana P. Bernardes
- Neha Mishra
- Florian Tran
- Thomas Bahmer
- Lena Best
- Johanna I. Blase
- Dora Bordoni
- Jeanette Franzenburg
- Ulf Geisen
- Jonathan Josephs-Spaulding
- Philipp Köhler
- Axel Künstner
- Elisa Rosati
- Anna C. Aschenbrenner
- Petra Bacher
- Nathan Baran
- Teide Boysen
- Burkhard Brandt
- Niklas Bruse
- Jonathan Dörr
- Andreas Dräger
- Gunnar Elke
- David Ellinghaus
- Julia Fischer
- Michael Forster
- Andre Franke
- Sören Franzenburg
- Norbert Frey
- Anette Friedrichs
- Janina Fuß
- Andreas Glück
- Jacob Hamm
- Finn Hinrichsen
- Marc P. Hoeppner
- Simon Imm
- Ralf Junker
- Sina Kaiser
- Ying H. Kan
- Rainer Knoll
- Christoph Lange
- Georg Laue
- Clemens Lier
- Matthias Lindner
- Georgios Marinos
- Robert Markewitz
- Jacob Nattermann
- Rainer Noth
- Peter Pickkers
- Klaus F. Rabe
- Alina Renz
- Christoph Röcken
- Jan Rupp
- Annika Schaffarzyk
- Alexander Scheffold
- Jonas Schulte-Schrepping
- Domagoj Schunk
- Dirk Skowasch
- Thomas Ulas
- Klaus-Peter Wandinger
- Michael Wittig
- Johannes Zimmermann
- Hauke Busch
- Bimba F. Hoyer
- Christoph Kaleta
- Jan Heyckendorf
- Matthijs Kox
- Jan Rybniker
- Stefan Schreiber
- Joachim L. Schultze
- Philip Rosenstiel
- HCA Lung Biological Network
- Deutsche COVID-19 Omics Initiative (DeCOI)
tags:
- '"COVID-19"'
- '"SARS-CoV-2"'
- '"acute respiratory distress"'
- '"Adult"'
- '"Aged"'
- '"Aged"'
- '"80 and over"'
- '"Biomarkers"'
- '"blood"'
- '"Blood Circulation"'
- '"Cells"'
- '"Cultured"'
- '"Cohort Studies"'
- '"Disease Progression"'
- '"disease trajectory"'
- '"Erythroid Cells"'
- '"Female"'
- '"Gene Expression Profiling"'
- '"Humans"'
- '"immune response"'
- '"infectious disease"'
- '"Male"'
- '"Megakaryocytes"'
- '"methylation"'
- '"Middle Aged"'
- '"Plasma Cells"'
- '"Proteomics"'
- '"RNA-seq"'
- '"scRNA-seq"'
- '"Sequence Analysis"'
- '"RNA"'
- '"Severity of Illness Index"'
- '"Single-Cell Analysis"'
- '"virus"'
categories: []
date: '2020-12-01'
lastmod: 2021-03-03T20:39:10+01:00
featured: false
draft: false

# Featured image
# To use, add an image named `featured.jpg/png` to your page's folder.
# Focal points: Smart, Center, TopLeft, Top, TopRight, Left, Right, BottomLeft, Bottom, BottomRight.
image:
  caption: ''
  focal_point: ''
  preview_only: false

# Projects (optional).
#   Associate this post with one or more of your projects.
#   Simply enter your project's folder or file name without extension.
#   E.g. `projects = ["internal-project"]` references `content/project/deep-learning/index.md`.
#   Otherwise, set `projects = []`.
projects: []
publishDate: '2021-03-03T19:39:10.110380Z'
publication_types:
- '2'
abstract: Temporal resolution of cellular features associated with a severe COVID-19
  disease trajectory is needed for understanding skewed immune responses and defining
  predictors of outcome. Here, we performed a longitudinal multi-omics study using
  a two-center cohort of 14 patients. We analyzed the bulk transcriptome, bulk DNA
  methylome, and single-cell transcriptome (textgreater358,000 cells, including BCR
  profiles) of peripheral blood samples harvested from up to 5 time points. Validation
  was performed in two independent cohorts of COVID-19 patients. Severe COVID-19 was
  characterized by an increase of proliferating, metabolically hyperactive plasmablasts.
  Coinciding with critical illness, we also identified an expansion of interferon-activated
  circulating megakaryocytes and increased erythropoiesis with features of hypoxic
  signaling. Megakaryocyte- and erythroid-cell-derived co-expression modules were
  predictive of fatal disease outcome. The study demonstrates broad cellular effects
  of SARS-CoV-2 infection beyond adaptive immune cells and provides an entry point
  toward developing biomarkers and targeted treatments of patients with COVID-19.
publication: '*Immunity*'
doi: 10.1016/j.immuni.2020.11.017
---
